CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells

Xu,Bing; Chen,Hui; Xu,Zhipeng; Yao,Xijuan; Sun,Xinchen; Cheng,Hongyan

doi:10.3892/mmr.2021.12169

CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells

Authors:
- Bing Xu
- Hui Chen
- Zhipeng Xu
- Xijuan Yao
- Xinchen Sun
- Hongyan Cheng
View Affiliations

Affiliations: Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Synthetic Internal Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: May 25, 2021 https://doi.org/10.3892/mmr.2021.12169
Article Number: 530
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cell division cycle‑associated 2 (CDCA2) overexpression has been demonstrated to serve a significant role in tumorigenesis in certain types of cancer. Nevertheless, its role in tumour proliferation and radioresistance in oesophageal squamous cell carcinoma (ESCC) remains to be elucidated. Thus, the present study aimed to elucidate these roles. Data were downloaded from The Cancer Genome Atlas (TCGA) to compare the gene expression profiles. The expression of CDCA2 was higher in ESCC tissues compared with normal tissues. Gene set enrichment analysis was performed based on the ESCC cohorts in TCGA database. This demonstrated that higher expression of CDCA2 was significantly associated with the expression of related components of the cell cycle phase transition and G2/M phase transition pathways. Collectively, the results revealed that CDCA2 could serve as an underlying target to regulate tumour growth and radioresistance among patients with ESCC.

View Figures

View References

1	Siegel RJ, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
4	Le Bras GF, Farooq MH, Falk GW and Andl CD: Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacol Res. 113A:A236–A244. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhao J, He YT, Zheng RS, Zhang SW and Chen WQ: Analysis of esophageal cancer time trends in China, 1989-2008. Asian Pac J Cancer Prev. 13:4613–4617. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ohashi S, Miyamoto S, Kikuchi O, Goto T, Amanuma Y and Muto M: Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology. 149:1700–1715. 2015. View Article : Google Scholar : PubMed/NCBI
7	Liang H, Fan JH and Qiao YL: Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 14:33–41. 2017. View Article : Google Scholar : PubMed/NCBI
8	van Rossum PSN, Mohammad NH, Vleggaar FP and van Hillegersberg R: Treatment for unresectable or metastatic oesophageal cancer: Current evidence and trends. Nat Rev Gastroenterol Hepatol. 15:235–249. 2018. View Article : Google Scholar : PubMed/NCBI
9	Dai T and Shah MA: Chemoradiation in oesophageal cancer. Best Pract Res Clin Gastroenterol. 29:193–209. 2015. View Article : Google Scholar : PubMed/NCBI
10	Prevost M, Chamousset D, Nasa I, Freele E, Morrice N, Moorhead G and Trinkle-Mulcahy L: Quantitative fragmentome mapping reveals novel, domain-specific partners for the modular protein RepoMan (recruits PP1 onto mitotic chromatin at anaphase). Mol Cell Proteomics. 12:1468–1486. 2013. View Article : Google Scholar : PubMed/NCBI
11	Feng Y, Qian W, Zhang Y, Peng W, Li J, Gu Q, Ji D, Zhang Z, Wang Q, Zhang D and Sun Y: CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo. BMC Cancer. 19:5762019. View Article : Google Scholar : PubMed/NCBI
12	Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, Ogawara K, Shiiba M, Bukawa H and Tanzawa H: Overexpression of CDCA2 in human squamous cell carcinoma: Correlation with prevention of G1 phase arrest and apoptosis. PLoS One. 8:e563812013. View Article : Google Scholar : PubMed/NCBI
13	Shi R, Zhang C, Wu Y, Wang X, Sun Q, Sun J, Xia W, Dong G, Wang A, Jiang F and Xu L: CDCA2 promotes lung adenocarcinoma cell proliferation and predicts poor survival in lung adenocarcinoma patients. Oncotarget. 8:19768–19779. 2017. View Article : Google Scholar : PubMed/NCBI
14	Peng A, Lewellyn AL, Schiemann WP and Maller JL: Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol. 20:387–396. 2010. View Article : Google Scholar : PubMed/NCBI
15	Vagnarelli P: Repo-man at the intersection of chromatin remodelling, DNA repair, nuclear envelope organization, and cancer progression. Adv Exp Med Biol. 773:401–414. 2014. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Zhao Y, Yi J, Tao L, Huang G, Chu X, Song H and Chen L: Wnt signaling induces radioresistance through upregulating HMGB1 in esophageal squamous cell carcinoma. Cell Death Dis. 9:4332018. View Article : Google Scholar : PubMed/NCBI
18	Dillon MT, Good JS and Harrington KJ: Selective targeting of the G2/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin Oncol (R Coll Radiol). 26:257–265. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sinclair WK and Morton RA: X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res. 29:450–474. 1966. View Article : Google Scholar : PubMed/NCBI
20	Terasima T and Tolmach LJ: Variations in several responses of HeLa cells to x-irradiation during the division cycle. Biophys J. 3:11–33. 1963. View Article : Google Scholar : PubMed/NCBI
21	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zheng N, Zhang S, Wu W, Zhang N and Wang J: Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. Pharmacol Res. 166:1055072021. View Article : Google Scholar : PubMed/NCBI
23	Petersen EV, Chudakova DA, Skorova EY, Anikin V, Reshetov IV and Mynbaev OA: The extracellular matrix-derived biomarkers for diagnosis, prognosis, and personalized therapy of malignant tumors. Front Oncol. 10:5755692020. View Article : Google Scholar : PubMed/NCBI
24	Krasnoselsky AL, Whiteford CC, Wei JS, Bilke S, Westermann F, Chen QR and Khan J: Altered expression of cell cycle genes distinguishes aggressive neuroblastoma. Oncogene. 24:1533–1541. 2005. View Article : Google Scholar : PubMed/NCBI
25	Xiao B, Chen L, Ke Y, Hang J, Cao L, Zhang R, Zhang W, Liao Y, Gao Y, Chen J, et al: Identification of methylation sites and signature genes with prognostic value for luminal breast cancer. BMC Cancer. 18:4052018. View Article : Google Scholar : PubMed/NCBI
26	Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI
27	He G, Di X, Yan J, Zhu C, Sun X and Zhang S: Silencing human epidermal growth factor receptor-3 radiosensitizes human luminal A breast cancer cells. Cancer Sci. 109:3774–3782. 2018. View Article : Google Scholar : PubMed/NCBI
28	Buckley AM, Lynam-Lennon N, O'Neill H and O'Sullivan J: Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 17:298–313. 2020. View Article : Google Scholar : PubMed/NCBI
29	Sadoughi F, Mirsafaei L, Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, Montazer M, Hosseinpour M and Yousefi B: The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem? DNA Repair (Amst). 101:1030742021. View Article : Google Scholar : PubMed/NCBI
30	Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L and Maher SG: Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. Radiat Res. 174:703–711. 2010. View Article : Google Scholar : PubMed/NCBI
31	Liu C, Gross N, Li Y, Li G, Wang Z, Zhong S, Li Y and Hu G: PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. J Cell Mol Med. 24:2444–2450. 2020. View Article : Google Scholar : PubMed/NCBI
32	Sak A and Stuschke M: Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol. 20:223–231. 2010. View Article : Google Scholar : PubMed/NCBI
33	Bouzinab K, Summers HS, Stevens MFG, Moody CJ, Thomas NR, Gershkovich P, Weston N, Ashford MB, Bradshaw TD and Turyanska L: Delivery of temozolomide and N3-propargyl analog to brain tumors using an apoferritin nanocage. ACS Appl Mater Interfaces. 12:12609–12617. 2020. View Article : Google Scholar : PubMed/NCBI
34	Maity A, McKenna WG and Muschel RJ: The molecular basis for cell cycle delays following ionizing radiation: A review. Radiother Oncol. 31:1–13. 1994. View Article : Google Scholar : PubMed/NCBI